Edoxaban
Coronary Atherosclerosis
Asan Medical CenterSmall moleculeUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Coronary Atherosclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isosorbide Dinitrate Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Bisoprolol Fumarate Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Rosuvastatin Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Aspirin Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Pioglitazone Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Ezetimibe Samsung Medical Center | Phase 4 | BB |
Corpril Ukrainian Medical Stomatological Academy | Phase 4 | BB |
Rimonabant Sanofi | Phase 3 | CC |
Same molecule, other indications
Edoxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →